The agreement will facilitate the import of HAVN Life's naturally derived GMP psilocybin to research institutions and researchers within the U.S. “at competitive prices” to alleviate “supply chain issues,” reported HAVN in a press release.

"HAVN Life is kicking off 2022 with strong partnerships in both our research and retail divisions, and we are very excited to start fulfilling purchase orders for our research customers with our new U.S. distribution partner, Mycrodose Therapeutics," said HAVN Life CEO, Tim Moore. "We've been working closely with Chad and his team, and are excited about the potential of this partnership."

In December 2021, Mycrodose added a Schedule I Import license, which allows the import of psilocybin and psilocin for clinical trials, research and development, analytical purposes and distribution.

According to HVN, “the interest and demand for psilocybin research in the United States have grown significantly in 2021 and continue to outpace supply in 2022.”

The firm noted that the DEA Increased the quota for psilocybin research in the U.S. Meanwhile HAVN and Mycrodose, have completed the first purchase order and delivery of naturally derived GMP raw psilocybin mushrooms from Jamaica into the United States.

Image By Ilona Szentivanyi.